Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

María Teresa Gómez-Casares; Juan Carlos Hernández-Boluda; Antonio Jiménez-Velasco; Joaquin Martínez-López; María Giovanna Ferrario; Irmina Gozalbo; Joana Gostkorzewicz; Rudi Subirá

doi:10.36469/9808

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:31985/feed

ISSN 2327-2236

Oncology

Vol. 5, Issue 2, 2018

November 29, 2017 EDT

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz, Rudi Subirá,

janus kinase (jak) inhibitorsplenomegalymyelofibrosisjakavi® (ruxolitinib)cost-effectiveness

ccby-4.0

• https://doi.org/10.36469/9808

JHEOR

Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, et al. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. JHEOR. 2017;5(2):162-174. doi:10.36469/9808

View more stats